Biotech News
AdvanCell Secures $112M Series C to Expand Radionuclide Cancer Therapies
AdvanCell, a radiopharmaceuticals biotech, has secured $112 million in an oversubscribed Series C financing round. The funding was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis, with additional participation from Morningside, Tenmile, Brandon Capital, and others. The investment
4 February 2025
Stay ahead of trends and best practices
